1-(2-fluorobenzyl)-3-butyl-8-(n-acetyl-4-aminobenzyl)-xanthine

This compound is a synthetic xanthine derivative and an experimental small molecule inhibitor of cytosolic phosphoenolpyruvate carboxykinase (cPEPCK). It has been studied primarily as a research tool to probe the function of cPEPCK in metabolic pathways. The compound is not approved for clinical use and has no known therapeutic indications. Its mechanism involves direct inhibition of the enzyme cPEPCK (phosphoenolpyruvate carboxykinase [GTP], cytosolic), which plays a key role in gluconeogenesis by catalyzing the conversion of oxaloacetate to phosphoenolpyruvate. Inhibition of this enzyme can impact glucose metabolism and is relevant for metabolic disease research[1][2].

Other names

N-(4-((3-butyl-1-((2-fluorophenyl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)methyl)phenyl)acetamideN-[4-{3-butyl–1–[(2-fluorophenyl)methyl]–2,6-dioxo–2,3,6,7-tetrahydro–1H-purin–8–yl}methyl]phenyl]acetamideN-(4-{[3-butyl‑1‑(2-fluorobenzyl)‑2,6-dioxo‑2,3,6,9-tetrahydro‑1H-purin‑8-y l]methyl}phen yl)acetamide